Vivani Medical (NASDAQ:VANI) Posts Earnings Results

Vivani Medical (NASDAQ:VANI) posted its earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08), FiscalAI reports.

Vivani Medical Stock Up 1.8%

Vivani Medical stock traded up $0.02 during midday trading on Wednesday, reaching $1.16. The stock had a trading volume of 108,889 shares, compared to its average volume of 298,091. The firm has a market cap of $100.03 million, a price-to-earnings ratio of -2.70 and a beta of 2.35. Vivani Medical has a 52-week low of $0.92 and a 52-week high of $1.92. The company has a fifty day moving average of $1.18 and a 200 day moving average of $1.31.

Insider Buying and Selling at Vivani Medical

In other Vivani Medical news, Director Gregg Williams purchased 1,587,301 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was purchased at an average cost of $1.26 per share, with a total value of $1,999,999.26. Following the purchase, the director owned 32,944,484 shares of the company’s stock, valued at approximately $41,510,049.84. The trade was a 5.06% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 53.30% of the company’s stock.

Institutional Trading of Vivani Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new stake in shares of Vivani Medical during the third quarter valued at $26,000. Susquehanna International Group LLP lifted its holdings in Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after buying an additional 16,200 shares in the last quarter. Jane Street Group LLC purchased a new stake in Vivani Medical in the 4th quarter valued at about $60,000. Renaissance Technologies LLC grew its stake in Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after acquiring an additional 53,127 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Vivani Medical in the 4th quarter worth about $174,000. Hedge funds and other institutional investors own 6.78% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright dropped their price target on Vivani Medical from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Vivani Medical presently has a consensus rating of “Hold” and a consensus price target of $3.50.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.